Equities research analysts expect that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will announce sales of $83.73 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from $73.76 million to $91.70 million. Ultragenyx Pharmaceutical reported sales of $61.71 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 35.7%. The firm is expected to report its next quarterly earnings results on Thursday, July 29th.
On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $348.73 million for the current fiscal year, with estimates ranging from $330.39 million to $372.02 million. For the next fiscal year, analysts anticipate that the business will post sales of $402.86 million, with estimates ranging from $324.30 million to $448.23 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 4th. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.78). The business had revenue of $99.40 million during the quarter, compared to the consensus estimate of $77.21 million. Ultragenyx Pharmaceutical had a negative net margin of 60.96% and a negative return on equity of 38.24%. The firm’s revenue for the quarter was up 173.7% compared to the same quarter last year. During the same period last year, the business posted ($2.05) EPS.
A number of analysts recently weighed in on the stock. Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $170.00 to $156.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 5th. Citigroup upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and cut their price target for the company from $160.00 to $151.00 in a research report on Thursday, May 6th. SVB Leerink assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Sunday, May 9th. They issued a “buy” rating and a $178.00 price target on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $160.00 to $151.00 in a report on Thursday, May 6th. Finally, Evercore ISI raised shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating and set a $144.00 price objective for the company in a research report on Wednesday, May 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $150.19.
You’re seeing it everywhere right now: The “beast of rising prices” is back. Inflation just hit its highest level since 2008. And American investors are getting scared. CNN’s Fear & Greed Index just indicated the most “Fear” we’ve seen in a while. In light of today’s strange market activity, the Finance PhD who called the dot-com bust in 2000 just released a new prediction. And his message is clear: You need to prepare for things to get a whole lot stranger.
Shares of NASDAQ:RARE opened at $91.34 on Friday. The firm has a market cap of $6.16 billion, a P/E ratio of -29.28 and a beta of 1.87. The company has a 50 day moving average price of $100.48. Ultragenyx Pharmaceutical has a fifty-two week low of $72.83 and a fifty-two week high of $179.65.
In related news, EVP Karah Herdman Parschauer sold 1,329 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, June 10th. The stock was sold at an average price of $100.00, for a total transaction of $132,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Erik Harris sold 375 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, July 6th. The stock was sold at an average price of $91.53, for a total value of $34,323.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,614 shares of company stock worth $4,141,046. 6.70% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC lifted its position in Ultragenyx Pharmaceutical by 0.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 18,781 shares of the biopharmaceutical company’s stock worth $2,600,000 after acquiring an additional 101 shares during the last quarter. Wells Fargo & Company MN lifted its position in Ultragenyx Pharmaceutical by 105.2% during the fourth quarter. Wells Fargo & Company MN now owns 84,643 shares of the biopharmaceutical company’s stock worth $11,717,000 after acquiring an additional 43,404 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $13,123,000. Rhumbline Advisers lifted its position in Ultragenyx Pharmaceutical by 10.1% during the fourth quarter. Rhumbline Advisers now owns 85,203 shares of the biopharmaceutical company’s stock worth $11,795,000 after acquiring an additional 7,818 shares during the last quarter. Finally, Xponance Inc. acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $254,000. Institutional investors and hedge funds own 99.71% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.
Read More: Liquidity
Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What’s a Black Swan?
7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future
When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.
The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.
IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.
And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.
But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.
View the “7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future”.
